Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa
Authors
Anne W. Lucky (ORCID: https://orcid.org/0000-0002-6115-7584)
Amy S. Paller (ORCID: https://orcid.org/0000-0001-6187-6549)
Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa
Anne W. Lucky, Amy S. Paller, Işın Sinem Bağcı, Hubert Chen et al.
Citations
7 citations
Journal
American Journal of Clinical Dermatology
Topics
Skin and Cellular Biology Research
Field-Weighted Citation Impact (FWCI)
8.06
article
Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa
Anne W. Lucky, Amy S. Paller, Işın Sinem Bağcı, Hubert Chen, Kristina Fitzgerald, Shireen V. Guide, Suma Krishnan, M. Peter Marinkovich, Brittani Agostini, Shi‐Jie Chen, Mercedes E. González, Meghan M Conner
article en
7 citations
Abstract
No abstract available for this paper.
Publication Tag
American Journal of Clinical DermatologyVol. 26(4)
Institutions
Northwestern University (US), Cincinnati Children's Hospital Medical Center (US), Children's Hospital of Orange County (US), Veterans Health Administration (US), 490 BioTech (United States) (US), Crystal Research (United States) (US), Stanford University (US)